Skip to main content

Kawasaki disease

Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Kawasaki disease article more useful, or one of our other health articles.

Synonyms: Kawasaki's disease, Kawasaki/Kawasaki's syndrome, mucocutaneous lymph node syndrome, infantile periarteritis nodosa, infantile polyarteritis nodosa

Kawasaki disease is an idiopathic self-limiting systemic vasculitis that most often affects children in the age range 6 months to 5 years. It predominantly affects children of Asian origin, particularly Japanese and Chinese populations (possibly because of genetic susceptibility) but there is an appreciable worldwide incidence. It was first described in 1967 by Tomisaku Kawasaki, a Japanese paediatrician.

It was originally thought to be a troubling but benign illness but it was later realised that deaths and significant morbidity occur through its major complication of coronary artery aneurysm formation. It has taken over from rheumatic fever as the most common cause of acquired childhood heart disease in the developed world1. Prior to its delineation, cases had been described and classified on histological grounds as infantile polyarteritis/periarteritis nodosa. Early diagnosis and early treatment are now strongly advocated to reduce complications and have been shown to do so.

Its characteristic features are outlined below:

Classical features of Kawasaki disease

  • Fever lasting ≥5 days.

  • Marked irritability of the child.

  • Erythema, swelling and desquamation affecting the skin of the extremities.

  • Bilateral conjunctivitis.

  • Rash.

  • Inflammation of the lips, mouth and/or tongue.

  • Cervical lymphadenopathy.

Continue reading below


The highest annual incidence is thought to occur in Japan at 2243.1 and 264.8 cases per 100,000 children aged under and over 5 years respectively2. The incidence appears to be rising year on year in Japan2.

The incidence of Kawasaki disease in Europe is 5-10 per 100,000 children aged under 5 years, with Ireland showing the highest incidence of up to 15.2 per 100,000 children aged under 5 years2. The higher incidence in Northeast Asians persists after migration to countries with low incidence.

There is clear variation in incidence with ethnicity, with a bias towards East Asian children. A study from Hawaii showed an annual incidence of 210 per 100,000 Japanese American children under 5 years, compared to 13 per 100,000 white children3.

The diagnosis is frequently missed, as the early stages mimic many viral infections. A study into diagnosis by UK GPs demonstrated a delay of more than 10 days between presentation and admission in 7% of cases4. At presentation, few typical clinical features were present.

85% of affected children are under the age of 5 years, with a peak incidence between the ages of 18 and 24 months.

It is more common in boys.

Aetiology and pathophysiology1

These remain a mystery, although a combination of an infective trigger and genetic susceptibility seems likely. Seasonal differences and epidemics seem to suggest an infective component but no single pathogen has yet been identified. A genetic component to susceptibility is assumed from the much higher incidence in Asian children, particularly those from Japan or Korea.

There is an increased incidence of a history of Kawasaki disease among the parents of a Kawasaki disease patient, and an increased incidence among siblings and extended family members of an index case. Family linkage studies and genome-wide association studies have shown that susceptibility and disease outcome, including aneurysm formation and response to intravenous immunoglobulin, are influenced by variants in several different genes and signalling pathways, which vary across populations5.

It is assumed that an infective agent (not necessarily a single one) triggers an abnormal immune response in certain individuals. The condition is caused by an autoimmune-mediated systemic vasculitis that affects small- and medium-sized arteries and in multiple organs and tissues during the acute febrile phase.

Continue reading below


Assess children with fever lasting five days or more for Kawasaki disease7.

Always ask parents whether the child has had any of the symptoms below since the onset of fever, because they may have resolved by the time of assessment7.

Be aware that children aged under 1 year may present with fewer clinical features of Kawasaki disease in addition to fever, but may be at higher risk of coronary artery abnormalities than older children7.


The usual presenting feature is a fever of abrupt onset. The child tends to be very irritable and unwell when febrile, often out of proportion to the severity of the fever. Most consider that the fever must have been present for at least five days for Kawasaki disease to be diagnosed; however, experienced clinicians may make the diagnosis earlier in its course, if there are other classical features. As well as fever of 39°C or more, there must be at least four of the following to fit the diagnostic criteria (or echocardiographic evidence of coronary artery aneurysms):

  • Inflammation and irritation of the lips, mouth and/or tongue (eg, cracked lips, strawberry tongue, inflamed mucosa of mouth or pharynx).

  • Erythema, oedema and/or desquamation of the extremities.

  • Bilateral dry conjunctivitis.

  • Widespread non-vesicular rash.

  • Cervical lymphadenopathy (which may be >1.5 cm in size).

These features may occur in turn, so some may have gone at the time of presentation; therefore, a careful history is important. Incomplete Kawasaki disease is the term given to those with fever but without enough other features to fit the diagnostic criteria. This is common - 15-20% of cases - and comes with an increased risk of complications, probably due to diagnostic delay.

Other possible features include lethargy, urethritis, diarrhoea, vomiting, abdominal pain, myalgia, arthralgia and arthritis, along with other less common features listed in the 'Subsidiary features of the disease' section below.


  • The lips typically become erythematous or fissured, along with inflamed oral mucosa and the presence of a 'strawberry tongue' - so-called because it is extremely erythematous with prominent papillae.

  • The rash is described as a polymorphic exanthem and comes on within 3-5 days of the onset of fever. It usually begins with nonspecific erythema of the soles, palms and perineum, spreading to involve the trunk and the rest of the extremities. It is often itchy and variable in appearance but is never vesiculo-bullous. It is usually markedly red and may appear macular, morbilliform, papular, scarlatiniform, urticarial, akin to erythema multiforme or be made up of very many tiny micropustules.

  • Desquamation may affect the perineal area, moving to the fingers and then the toes. In the extremities, it usually begins in the periungual region.

  • The hands and feet often become red and swollen and tender before desquamation begins.

  • The conjunctivitis is never associated with exudate, is bilateral and tends to spare the perilimbal area.

  • Cervical lymphadenopathy is usually unilateral and non-tender, and affects the anterior cervical chain.

  • Cardiovascular signs are usually nonspecific. Tachycardia, a hyperdynamic precordium, a gallop rhythm or a flow murmur may be present; however, these signs are not unusual in febrile patients without Kawasaki disease. There are occasionally signs of valvular incompetence.

  • Other possible signs include:

    • Neck stiffness due to aseptic meningitis.

    • Hepatomegaly and jaundice.

Phases of the illness

The disease typically follows three phases, as outlined in the table below:


Time from fever onset

Predominant features


1-2 weeks

Highly febrile.

Very irritable.


Oral changes rapidly following.

Oedema and erythema of feet.

Rash especially common in the perineal area.


2-8 weeks

Gradual improvement.

The fever settles.

Desquamation of the perineum, palms, soles.

Arthritis, arthralgia.


Coronary artery aneurysms.

Myocardial infarction.


Months to years

Resolution of remaining symptoms.

Laboratory values return to normal.

Aneurysms may resolve or persist.

Beau's lines.

Cardiac dysfunction and myocardial infarction may still occur.

Subsidiary features of the disease

  • Cardiovascular - pancarditis, aortic or mitral incompetence.

  • Gastrointestinal - hydrops of gallbladder, jaundice, diarrhoea.

  • Blood - mild anaemia.

  • Renal - sterile pyuria, mild proteinuria.

  • CNS - aseptic meningitis.

  • Musculoskeletal - arthritis, arthralgia.

  • Others - anterior uveitis, BCG-site inflammation8.

Continue reading below

Differential diagnosis


  • There is no diagnostic test for the condition. Diagnosis is made clinically and depends on the presence of the diagnostic features described above.

  • Urinalysis may show sterile pyuria ± proteinuria.

  • FBC during the acute phase usually shows leukocytosis and neutrophilia, and acute-phase reactant markers such as ESR and CRP are usually elevated.

  • Platelets are elevated and there may be a marked thrombocythaemia that develops throughout the second and third weeks of the illness.

  • LFTs may show elevation of the transaminases and bilirubin.

  • Abdominal ultrasound can show evidence of gallbladder distension.

  • ECG may show a range of conduction abnormalities due to carditis.

  • Echocardiography is essential. It can reveal dilatation and aneurysms of the coronary arteries, as well as allowing assessment of the pericardium and left ventricular/valvular function. Serial echocardiography is often needed to detect occult coronary artery disease as the illness evolves.

Evaluation of suspected incomplete Kawasaki disease5

In children with fever for five or more days and two or three compatible clinical criteria, or in infants with fever for seven or more days without other explanation, a scientific statement from the American Heart Association recommends:

  • If CRP is <3.0 mg/dL and ESR is <40 mm/hr, perform serial clinical and laboratory re-evaluation if fevers persist, and echocardiogram if typical peeling develops.

  • If CRP is ≥3.0 mg/dL and/or ESR is ≥40 mm/hr, look for:

    • Positive echocardiogram; or

    • Three or more of:

      • Anaemia for age.

      • Platelet count ≥450 x109/L after seventh day of fever.

      • Albumin ≤3.0 g/dL.

      • Raised ALT.

      • WBC ≥15 x 109/L.

      • Urine WBC ≥10/high power field.

    • If either of the above applies, treat.

    • If neither of the above applies, perform serial clinical and laboratory re-evaluation if fevers persist, and echocardiogram if typical peeling develops.


  • Children with the condition are usually cared for as inpatients on paediatric or paediatric-cardiology units and put on bed rest, due to the risk of myocardial events.

  • The mainstays of management are the use of aspirin and intravenous immunoglobulin (IVIg) to reduce fever and myocardial inflammation and to prevent or ameliorate cardiac sequelae (the main cause of morbidity and mortality associated with the condition).

  • In some countries, corticosteroids are used additionally in severe cases.

  • Follow-up echocardiography is useful in determining whether or not there have been any coronary artery complications.

  • Percutaneous coronary intervention and coronary artery bypass grafting may be indicated in very severe cases with cardiac complications.


The routine use of aspirin in the management of febrile children is not recommended due to the danger of Reye's syndrome.

However, in Kawasaki disease, the antiplatelet and antipyretic effect of the drug provides the rationale for its use. The drug is used widely in a variety of high-dose and low-dose regimens, both in the acute and subsequent phases, and as long-term prophylaxis against coronary events in those who have coronary artery aneurysms. There is a scant evidence base to support its use and little useful research to decide on the optimal regimen. Usually higher doses are used in the acute inflammatory phases, followed by a lower antiplatelet dose in later phases.

A Cochrane review in 2006 concluded that until good-quality randomised controlled trials are carried out, there is insufficient evidence to indicate whether children with Kawasaki disease should continue to receive aspirin as part of their treatment regimen10.


IVIg is the mainstay of treatment. It has been shown to reduce the incidence of coronary artery aneurysms from about 25% in the untreated to approximately 4%5. 2 g/kg as a single infusion over 10-12 hours, together with aspirin, is the standard regime.

IVIg resistance is a problem in as many as 20% of cases and these children are at risk of cardiac complications unless they receive additional therapy. This may then be in the form of further IVIg, or corticosteroids, or a number of other possibilities.

Children treated with IVIg should have immunisations with live vaccines (eg, MMR) delayed for 3-11 months after treatment (UK recommendation is 3 months).

Adjunctive therapy in refractory cases

Approximately 10% to 20% of patients do not respond to initial intravenous immune globulin. For these patients, alternative treatments may be considered. Patients believed to be at high risk for development of coronary artery aneurysms may benefit from primary adjunctive therapy5.

The following agents have been used:

  • Corticosteroids. These have traditionally been avoided, as early studies suggested they increased the complication rate. However, a meta-analysis in Japan showed addition of prednisolone in a dose of 2 mg/kg/day to IVIg treatment reduced coronary complications11. Evidence is not yet convincing enough for steroids to be used routinely as part of primary treatment but they may have a useful role in those with IVIg resistance. Research continues on how to predict this population.

  • Anti-tumour necrosis factor (anti-TNF)-alpha therapies:

    • Infliximab (monoclonal antibody acting as TNF-alpha antagonist)12.

    • Etanercept (a soluble TNF-alpha receptor)13.

  • Other immunosuppressive therapy:

    • Ciclosporin.

    • Cyclophosphamide.

    • Low-dose methotrexate14.

  • Plasma exchange.

Management of coronary artery aneurysms

This is also an area of uncertainty. A paediatric cardiologist should be involved if there is evidence of dilation of coronary arteries. Regular echocardiograms and tests of cardiac function are required.

Percutaneous coronary intervention may be required for those at high risk of cardiac ischaemia, such as:

  • Intracoronary thrombolysis

  • Balloon angioplasty

  • Cardiac stents

  • Ablation therapy

Occasionally, coronary artery bypass surgery may be needed.

Long-term antiplatelet/anticoagulant therapies will be required, usually aspirin with either warfarin or low molecular weight heparin.


Recurrence of the condition (estimated to affect less than 1%)6.


  • Prognosis depends upon the degree of cardiac involvement.

  • Although the majority of patients do well and do not experience major complications, up to 50% show echocardiographic evidence of cardiac impairment and mild mitral regurgitation.

  • 15-25% of untreated patients will experience coronary artery aneurysms but this figure is much lower if early diagnosis and therapy are achieved. 1% become giant aneurysms (>8 mm internal diameter)15.

  • Most (50-70%) coronary artery aneurysms regress after a period of 1-2 years, although giant aneurysms never resolve entirely and have a worse prognosis.

  • Mortality varies between populations and treating centres but is in the range 0.08-3.7%. In the UK there were no reported deaths from Kawasaki disease in the period January 2013 to January 2015 in an analysis by the British Paediatric Surveillance Unit (BPSU)16.

  • Follow-up in later life is recommended. Kawasaki disease is a relatively new disease, and the long-term cardiac implications are not yet fully known.

  • Kawasaki disease is not contagious.

Further reading and references

  1. Eleftheriou D, Levin M, Shingadia D, et al; Management of Kawasaki disease. Arch Dis Child. 2014 Jan;99(1):74-83. doi: 10.1136/archdischild-2012-302841. Epub 2013 Oct 25.
  2. Lin M-T, Wu M-H.The global epidemiology of Kawasaki disease: Review and future perspectives. Glob Cardiol Sci Pract. 2017 Oct 31; 2017(3): e201720.
  3. Nakamura Y, Yashiro M, Uehara R, et al; Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey. J Epidemiol. 2012;22(3):216-21. Epub 2012 Mar 10.
  4. Moore A, Harnden A, Mayon-White R; Recognising Kawasaki disease in UK primary care: a descriptive study using the Clinical Practice Research Datalink. Br J Gen Pract. 2014 Aug;64(625):e477-83. doi: 10.3399/bjgp14X680953.
  5. McCrindle BW, Rowley AH, Newburger JW, et al; Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017 Apr 25;135(17):e927-e999. doi: 10.1161/CIR.0000000000000484. Epub 2017 Mar 29.
  6. Harnden A, Tulloh R, Burgner D; Kawasaki disease. BMJ. 2014 Sep 17;349:g5336. doi: 10.1136/bmj.g5336.
  7. Fever in under 5s: assessment and initial management; NICE Guidance (last updated November 2021)
  8. Chalmers D, Corban JG, Moore PP; BCG site inflammation: a useful diagnostic sign in incomplete Kawasaki disease. J Paediatr Child Health. 2008 Sep;44(9):525-6.
  9. Jamieson N, Singh-Grewal D; Kawasaki Disease: A Clinician's Update. Int J Pediatr. 2013;2013:645391. doi: 10.1155/2013/645391. Epub 2013 Oct 27.
  10. Baumer JH, Love SJ, Gupta A, et al; Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004175.
  11. Chen S, Dong Y, Yin Y, et al; Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart. 2013 Jan;99(2):76-82. doi: 10.1136/heartjnl-2012-302126. Epub 2012 Aug 6.
  12. Dominguez SR, Anderson MS; Advances in the treatment of Kawasaki disease. Curr Opin Pediatr. 2013 Feb;25(1):103-9. doi: 10.1097/MOP.0b013e32835c1122.
  13. Choueiter NF, Olson AK, Shen DD, et al; Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease. J Pediatr. 2010 Dec;157(6):960-966.e1. doi: 10.1016/j.jpeds.2010.06.014. Epub 2010 Jul 27.
  14. Lee TJ, Kim KH, Chun JK, et al; Low-dose Methotrexate Therapy for Intravenous Immunoglobulin-resistant Kawasaki Disease. Yonsei Med J. 2008 Oct 31;49(5):714-8.
  15. Golshevsky D, Cheung M, Burgner D; Kawasaki disease--the importance of prompt recognition and early referral. Aust Fam Physician. 2013 Jul;42(7):473-6.
  16. BPSU Annual Report 2013-2014; British Paediatric Surveillance Unit

Article history

The information on this page is written and peer reviewed by qualified clinicians.

symptom checker

Feeling unwell?

Assess your symptoms online for free